Nivolumab & Relatlimab-Rmbw (Opdualag™) Mann, Janelle E. Mann, Janelle E. Less Oncology Times. 44(10):16,18, May 20, 2022. Favorite PDF Permissions Free
AI Can Help Predict Success of Melanoma Treatment With CT Scans McGraw, Mark McGraw, Mark Less Oncology Times. 44(8):33, April 20, 2022. Favorite PDF Permissions Free
Nivolumab + Relatlimab Continues Clinical Benefit in Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(8):27, April 20, 2022. Favorite PDF Permissions Free
Tebentafusp-tebn (Kimmtra®) Mehringer, Rachel Mehringer, Rachel Less Oncology Times. 44(6):12,16, March 20, 2022. Favorite PDF Permissions Free
The Value of a High-Fiber Diet for Melanoma Patients on Immunotherapy Froelich, Warren Froelich, Warren Less Oncology Times. 44(4):16-17, February 20, 2022. Favorite PDF Permissions Free CME Test
A Closer Look at Skin Cancer Screening & Its Benefits Jenks, Susan Jenks, Susan Less Oncology Times. 44(3):21, February 5, 2022. Favorite PDF Permissions Free
High-Fiber Diet May Improve Response of Melanoma Patients to Immunotherapy Less Oncology Times. 44(2):32, January 20, 2022. Favorite PDF Permissions Free
Changes in DNA Allow Melanomas to Develop Drug Resistance Less Oncology Times. 44(2):23, January 20, 2022. Favorite PDF Permissions Free
On Estrogens & Their Effects on Melanoma Galamba, Elizabeth Rose Galamba, Elizabeth Rose Less Oncology Times. 44(2):19, January 20, 2022. Favorite PDF Permissions Free
Initial Immunotherapy Tops Targeted Therapy for Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 44(1):19, January 5, 2022. Favorite PDF Permissions Free
Searching for Therapies to Treat Rare Ocular Melanoma Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 44(1):1,13-14, January 5, 2022. Favorite PDF Permissions Free
Superior Recurrence-Free Survival in Melanoma Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(22):22, November 20, 2021. Favorite PDF Permissions Free
TIL Therapy Dissolves Metastatic Melanoma Tumors, Other Cancers Holt, Chuck Holt, Chuck Less Oncology Times. 43(19):29,41, October 5, 2021. Favorite PDF Permissions Free
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Less Oncology Times. 43(18):30, September 20, 2021. Favorite PDF Permissions Free
Topical HDAC Inhibitor Gel Treats Basal Cell Carcinoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(18):14, September 20, 2021. Favorite PDF Permissions Free
Cell-Based Immunotherapy Shows Promise Against Melanoma Less Oncology Times. 43(15):22, August 5, 2021. Favorite PDF Permissions Free
Gut Microbes Linked to Toxicity in Checkpoint Inhibitors for Melanoma Less Oncology Times. 43(15):20, August 5, 2021. Favorite PDF Permissions Free
Immunotherapy Combo Checks Progression in Advanced Melanoma Samson, Kurt Samson, Kurt Less Oncology Times. 43(13):29, July 5, 2021. Favorite PDF Permissions Free
Clinical Outcomes of Early Immunotherapy Cessation in Metastatic Melanoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(11):28,43, June 5, 2021. Favorite PDF Permissions Free
Environmental Interventions Targeting Skin Cancer in Children Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(8):26, April 20, 2021. Favorite PDF Permissions Free
Fecal Microbiota Transplants for Patients With Advanced Melanoma Less Oncology Times. 43(5):30, March 5, 2021. Favorite PDF Permissions Free
Uveal Melanoma: Current Treatments & New Approaches on the Horizon Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(5):6-7, March 5, 2021. Favorite PDF Permissions Free CME Test
Age As Primary Determinant of Melanoma Treatment Resistance Less Oncology Times. 42(23):23-26, December 5, 2020. Favorite PDF Permissions Free
Immunotherapy for Metastatic Cutaneous Squamous Cell Carcinoma Holt, Chuck Holt, Chuck Less Oncology Times. 42(23):18, December 5, 2020. Favorite PDF Permissions Free
Risk of Melanoma May Be Gauged By Accumulated DNA Damage Less Oncology Times. 42(21):20, November 5, 2020. Favorite PDF Permissions Free
Successful Discontinuation of PD-1 Inhibitors in Metastatic Melanoma Hackethal, Veronica Hackethal, Veronica Less Oncology Times. 42(16):33, August 20, 2020. Favorite PDF Permissions Free
Adjuvant Immunotherapy Offers Survival Benefit Among Some Melanoma Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 42(15):36, August 5, 2020. Favorite PDF Permissions Free
Triple Combination Prolongs Survival in Advanced BRAF V600 Melanoma Froelich, Warren Froelich, Warren Less Oncology Times. 42(12):35, June 20, 2020. Favorite PDF Permissions Free
New Therapies Cause Sharp Drop in Melanoma Mortality Rates Wolfgang, Kelly Wolfgang, Kelly Less Oncology Times. 42(11):24-28, June 5, 2020. Favorite PDF Permissions Free
Gay & Bisexual Men Have Higher Rate of Skin Cancer Less Oncology Times. 42(9):8-12, May 5, 2020. Favorite PDF Permissions Free
Liquid Biopsy as Effective Predictor of Stage III Melanoma Relapse Lucci, Anthony; Hall, Carolyn Lucci, Anthony; Hall, Carolyn Less Oncology Times. 42(6):9,18, March 20, 2020. Favorite PDF Permissions Free
Oral Hedgehog Inhibitors for Advanced Basal Cell Carcinoma Prezzano, James C.; Ibrahim, Sherrif F. Prezzano, James C.; Ibrahim, Sherrif F. Less Oncology Times. 42(5):1,14, March 5, 2020. Favorite PDF Permissions Free
Study Finds 95 Percent Satisfaction Rate With Mohs Surgery Less Oncology Times. 42(3):21, February 5, 2020. Favorite PDF Permissions Free
Discovery of a Metabolic Feature That Allows Melanoma Cells to Spread Less Oncology Times. 42(2):19, January 20, 2020. Favorite PDF Permissions Free
New Guideline on Radiation Therapy for Basal, Squamous Cell Skin Cancers Less Oncology Times. 42(1):27, January 5, 2020. Favorite PDF Permissions Free
Best Practices Established for Melanoma Neoadjuvant Therapy Hepp, Rebecca Hepp, Rebecca Less Oncology Times. 41(18):1,4, September 20, 2019. Favorite PDF Permissions Free
Genetic Testing Motivates Behavior Changes in Families at Risk for Melanoma Less Oncology Times. 41(16):26, August 20, 2019. Favorite PDF Permissions Free
Immunotherapy for Patients With Melanoma Metastatic to the Brain Holt, Chuck Holt, Chuck Less Oncology Times. 41(16):1,4,6, August 20, 2019. Favorite PDF Permissions Free
Binimetinib (Mektovi®) Finnes, Heidi D. Finnes, Heidi D. Less Oncology Times. 41(14):8, July 20, 2019. Favorite PDF Permissions Free
HDAC Inhibitor Primes Immunotherapy in Resistant Melanoma Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 41(10):37, May 20, 2019. Favorite PDF Permissions Free
Immunotherapy to Prevent Squamous Cell Carcinoma Less Oncology Times. 41(8):18, April 20, 2019. Favorite PDF Permissions Free
Melanoma Brain Metastases & Treatment-Resistant Metabolism Less Oncology Times. 41(6):18, March 20, 2019. Favorite PDF Permissions Free
3 Questions on... Whether Obesity Protects Against Skin Cancer or Not: With Delphine Lee, MD, PhD, Chief of the Division of Dermatology at Harbor-UCLA Medical Center DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 41(5):40, March 5, 2019. Favorite PDF Permissions Free
Immunotherapy Drug as First-Line Therapy for Merkel Cell Carcinoma Less Oncology Times. 41(5):18, March 5, 2019. Favorite PDF Permissions Free
Melanoma Classifications in the Age of Precision Medicine Samson, Kurt Samson, Kurt Less Oncology Times. 41(5):16,21, March 5, 2019. Favorite PDF Permissions Free
Proton Pump Inhibitor Therapy & Nivolumab Plus Ipilimumab in Melanoma Less Oncology Times. 41(2):37, January 20, 2019. Favorite PDF Permissions Free
The COLUMBUS Trial in Metastatic Melanoma—New Peer-Reviewed Data Hamid, Omid Hamid, Omid Less Oncology Times. 41(1):1,8-9, January 5, 2019. Favorite PDF Permissions Free
Combination Approach Shows Promise for Beating Advanced Melanoma Less Oncology Times. 40(18):36, September 20, 2018. Favorite PDF Permissions Free
Combination Immunotherapy Shrinks Melanoma Brain Metastases Less Oncology Times. 40(18):35, September 20, 2018. Favorite PDF Permissions Free
Newly Approved Combination Offers Hope for Metastatic Melanoma Kirkwood, John M. Kirkwood, John M. Less Oncology Times. 40(16):15,33, August 20, 2018. Favorite PDF Permissions Free
Innovative CRISPR Study Recreates Genetic Steps in Melanoma Less Oncology Times. 40(15):28, August 5, 2018. Favorite PDF Permissions Free
Trust Your Gut: The Microbiome & Metastatic Melanoma Holt, Chuck Holt, Chuck Less Oncology Times. 40(11):12-13, June 5, 2018. Favorite PDF Permissions Free
Pembrolizumab Shows Reduced Risk for Recurrence in Melanoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(10):33, May 20, 2018. Favorite PDF Permissions Free
The Reality of Precision Medicine in Metastatic Melanoma Weber, Jeffrey S. Weber, Jeffrey S. Less Oncology Times. 40(6):1-5, March 20, 2018. Favorite PDF Permissions Free
Presurgical Targeted Therapy Delays Relapse of High-Risk Stage III Melanoma Less Oncology Times. 40(3):27, February 5, 2018. Favorite PDF Permissions Free
Molecular Profiling Explains Survival of Melanoma Cells After Therapy Less Oncology Times. 39(24):33, December 25, 2017. Favorite PDF Permissions Free
Gut Bacteria Modulates Response to Immunotherapy in Melanoma Less Oncology Times. 39(22):49, November 25, 2017. Favorite PDF Permissions Free
Adjuvant Nivolumab Superior to Ipilimumab in High-Risk Melanoma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 39(21):37, November 10, 2017. Favorite PDF Permissions Free
Melanoma Cells Rewire to Resist Drug Treatment Less Oncology Times. 39(21):24, November 10, 2017. Favorite PDF Permissions Free
Binimetinib & Encorafenib for Patients With Melanoma Less Oncology Times. 39(20):25, October 25, 2017. Favorite PDF Permissions Free
Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma Less Oncology Times. 39(15):32, August 10, 2017. Favorite PDF Permissions Free
Long-Term Survival Extended in Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 39(13):32, July 10, 2017. Favorite PDF Permissions Free
FDA Approves First Treatment for Rare Form of Skin Cancer Less Oncology Times. 39(9):36, May 10, 2017. Favorite PDF Permissions Free
Electronic Brachytherapy for Nonmelanoma Skin Cancer Stegman, Lauren D. Stegman, Lauren D. Less Oncology Times. 39(9):38-39, May 10, 2017. Favorite PDF Permissions Free
ImmunoPulse IL-12 Receives Fast Track Designation for Melanoma Less Oncology Times. 39(7):4, April 10, 2017. Favorite PDF Permissions Free
Translation Reprogramming Key Determinant of Melanoma Invasion Goding, Colin Goding, Colin Less Oncology Times. 39(6):1,8, March 25, 2017. Favorite PDF Permissions Free
Patient Self Checks Are Critical to Avoid Melanoma Recurrence Less Oncology Times. 39(5):18, March 10, 2017. Favorite PDF Permissions Free
Combination Therapy for Metastatic Melanoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 39(2):1,8-9, January 25, 2017. Favorite PDF Permissions Free
Predicting Patient Responses to Melanoma Treatment Less Oncology Times. 38(23):38,42, December 10, 2016. Favorite PDF Permissions Free
Anti-IDO1 Combination Improves Progression-Free Melanoma Survival Samson, Kurt Samson, Kurt Less Oncology Times. 38(23):22, December 10, 2016. Favorite PDF Permissions Free
Adjuvant Ipilimumab Brings Longer Survival With Stage III Melanoma Goodwin, Peter M. Goodwin, Peter M. Less Oncology Times. 38(22):38,41, November 25, 2016. Favorite PDF Permissions Free
How Does Melanoma Spread to Other Organs in the Body? Less Oncology Times. 38(17):16, September 10, 2016. Favorite PDF Permissions Free
Optical Coherence Tomography for Skin Cancer Wang, Katie; Levine, Amanda; Markowitz, Orit Wang, Katie; Levine, Amanda; Markowitz, Orit Less Oncology Times. 38(17):15-16, September 10, 2016. Favorite PDF Permissions Free
Dabrafenib Plus Trametinib Improves Survival in Advanced Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(13):16, July 10, 2016. Favorite PDF Permissions Free
Merkel Cell Carcinoma Responds to PD-1 Inhibitor Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 38(12):27, June 25, 2016. Favorite PDF Permissions Free
Phosphodiesterase Inhibitors Linked to Melanoma Susman, Ed Susman, Ed Less Oncology Times. 38(11):27, June 10, 2016. Favorite PDF Permissions Free
Ski Slopes & Cane Fields Present Melanoma Risks Susman, Ed Susman, Ed Less Oncology Times. 38(11):26, June 10, 2016. Favorite PDF Permissions Free
Melanoma Immunotherapy: We've Come a Long Way O'Donnell-Tormey, Jill O'Donnell-Tormey, Jill Less Oncology Times. 38(8):1,9,21-21, April 25, 2016. Favorite PDF Permissions Free
FDA Approves Opdivo-Yervoy Combo, Opdivo Single-Agent Therapy for New Indications in Metastatic Melanoma Less Oncology Times. 38(4):24, February 25, 2016. Favorite PDF Permissions Free
FDA Approves Tafinlar+Mekinist Combo for Melanoma Less Oncology Times. 38(3):35, February 10, 2016. Favorite PDF Permissions Free
FDA Approves Keytruda for Melanoma Less Oncology Times. 38(2):27, January 25, 2016. Favorite PDF Permissions Free
POINT-COUNTERPOINT: Does Sentinel Lymph Node Biopsy Extend Survival in Melanoma? Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 38(2):28-29, January 25, 2016. Favorite PDF Permissions Free
FDA Approves Opdivo as Single Agent for Melanoma Less Oncology Times. 38(1):41, January 10, 2016. Favorite PDF Permissions Free
FDA Breakthrough Therapy Designation to Avelumab for Merkel Cell Carcinoma Less Oncology Times. 37(24):32, December 25, 2015. Favorite PDF Permissions Free
Indications that Radiation Can Enhance Immunotherapy's Effects in Metastatic Melanoma Carlson, Robert H. Carlson, Robert H. Less Oncology Times. 37(24):38, December 25, 2015. Favorite PDF Permissions Free
FDA Approves Cotellic Combo Therapy for Advanced Melanoma Less Oncology Times. 37(23):57, December 10, 2015. Favorite PDF Permissions Free
FDA Approves First Oncolytic Virus Therapy: Imlygic for Melanoma Less Oncology Times. 37(23):36, December 10, 2015. Favorite PDF Permissions Free
Ipilimumab Approved for Adjuvant Use in Melanoma Less Oncology Times. 37(23):2, December 10, 2015. Favorite PDF Permissions Free
Opdivo-Yervoy Combination Approved for Melanoma—First Combination-Immunotherapy Regimen for Cancer Less Oncology Times. 37(21):39, November 10, 2015. Favorite PDF Permissions Free
The Lymphoma-Melanoma Connection Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(18):1,26-28, September 25, 2015. Favorite PDF Permissions Free
Priority Review to Keytruda for First-Line Treatment of Advanced Melanoma Less Oncology Times. 37(17):40, September 10, 2015. Favorite PDF Permissions Free
Melanoma: Amid Caveats, New Test Predicts Metastasis and Survival Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(17):26-29, September 10, 2015. Favorite PDF Permissions Free
Weighing Treatment Decisions in Melanoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 37(16):16-17, August 25, 2015. Favorite PDF Permissions Free
